The Ministry of External Affairs reported today (5) that there is no official ban on the Indian government for exporting vaccine supplements against new coronaviruses produced by pharmaceutical companies in that country.
According to a note issued by the Ministry of External Affairs, Aliso Franco, the Executive Secretary of the Ministry of Health, met the Ambassador of India in Brisilia yesterday (4) to discuss the matter.
“Negotiations between Oswaldo Cruz Foundation (FiroCruz) and Serum Institute of India for the initial import by Brazil against Kovid-19 for an initial amount of antibodies are at an advanced stage, with a possible delivery date in mid-January. The note, signed by Itamarty in association with the Ministry of Health, states.
On December 31, 2020, the National Health Surveillance Agency (ENVISA) imported from Oxford an extraordinary base of 2 million doses of the British vaccine, produced in partnership with the Oswaldo Cruise Foundation (FiroCruz in Brazil). Imported supplements were manufactured in India. In a meeting with representatives of Foveroos, Envisa said it needed more information for the emergency use of the vaccine in Brazil.
Yesterday (4), Adar Poonawalla, the head of the Serum Institute of India, even said through a note that exports would be prohibited by the Indian government unless part of the local population was vaccinated. At the time, Fukroz said the Ministry of External Affairs was in talks with health officials in India over the import of vaccine supplements.
In a note jointly signed with Krishna Ella, director of the Indian laboratory Bharat Biotech, Poonawalla denied the statement about the ban on the export of vaccines. The company produces Kovid-19, another vaccine against kovaxin. The company is in talks to sell 5 million doses of the vaccine to the Brazilian Association of Vaccine Clinics (ABCVAC).
In the note, representatives from the two laboratories highlighted the joint intention to supply vaccines to India and “globally” and the two companies continued to develop vaccine activities as planned.
The statement said, “Now that the two vaccines have received authorization for emergency use in India, the focus has been on manufacturing, supply and distribution, so that the population in greatest need receives high quality, safe and effective vaccines.” Be. “